Purdue University research tool in early development of FDA-approved advanced prostate cancer diagnosis and treatment

WEST LAFAYETTE, Ind. Prostate cancer is the second most common cancer in American men after non-melanoma skin cancer. It is also one of the leading causes of cancer death in men, according to the Centers for Disease Control and Prevention.

A new precision treatment that gives hope to patients with advanced prostate cancer has been approved by the US Food and Drug Administration. In a Phase III study, it was shown that treatment plus standard of care reduced the risk of death by 38% compared with standard care alone.

Groundbreaking research by Philip Low, Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry in the Department of Chemistry at Purdue University College of Science, has laid the groundwork for targeted therapy. exact target. After his initial research, Low disclosed it to the Purdue Research Foundation’s Office of Technology Commercialization.

“I just feel blessed to have had the opportunity to work on meaningful projects throughout my career and even more fortunate to have an impact on an unnecessary source of pain and illness.” Low said. “I suspect that most people know someone with prostate cancer, and it’s rewarding to finally be able to make an impact on this terrible disease.”

Purdue Resources for Commercialization of Intellectual Property

Brooke Beier, senior vice president of commercialization at the Purdue Research Foundation, said the FDA’s approval of precision-targeted therapy was one of the most significant approvals ever for a related innovation. regarding Purdue. Several technology transfer experts have carried out PRF’s mission by reviewing, patenting, and licensing Low’s innovations.

“We are incredibly proud of Dr Low and Boilermaker’s overall contribution to groundbreaking research and the foundational intellectual property that paved the way for this precisely targeted therapy, and we are delighted,” Beier said. Glad it got FDA approval.” “PRF aims to improve the world through the technologies of Purdue and its graduates; this is a perfect example of achieving that mission. We are excited about the potential of the material. this approach in supporting patients in their battle against end-stage prostate cancer.

“The Office of Technology Commercialization receives more than 400 invention disclosures from researchers each year and licenses more than 200 technologies annually. We continue to look for partners to commercialize these technologies. and work closely with them to support their efforts to bring technology to market to improve the world.”

Purdue’s research pipeline for drug discovery and development

Low worked on this innovation at the Purdue Institute for Drug Discovery, where he was its first director. The Institute supports faculty members in turning their discoveries into clinical trials with the ultimate goal of FDA approval. It currently supports more than 80 drugs in its development, with 18 currently in human clinical trials.

Zhong-Yin Zhang, the institute’s current director, said: “I am delighted to see that the FDA has approved a second drug in the past year based on science developed in Philip Low’s lab in the Institute. Purdue Drug Discovery These approvals show the power of drug discovery and development within the institute and at Purdue. The Institute for Drug Discovery is proud to support the work of Philip and all of their affiliated departments. me in turning their fundamental discoveries into life-saving drugs.”

The Purdue Center for Cancer Research (PCCR) is a basic cancer research center designed by the National Cancer Institute since 1978, one of only seven in the country. Timothy L. Ratliff, Robert Wallace Miller, Center Director, is proud of PCCR’s commitment to developing new cancer treatments.

“The FDA’s approval of this drug is another success story about Purdue’s strengths in cancer research,” said Ratliff. others will use to treat cancer”. “The foundation of these fundamental discoveries are researchers like Philip and their strengths in chemistry, pharmacogenomics, engineering, veterinary medicine, nutritional science, pharmaceutics, structural biology and science. students study.

“I am proud that PCCR has laid the foundation for the development of this first-class targeted radiation therapy not only through supporting the basic science but also through conducting the first clinical trial in who confirm the ability to deliver specific agents to prostate cancer cells.”

Philip Low’s Other Impact on Drug Discovery and Development

On November 29, the FDA approved another Low’s initiative, a drug designed to help surgeons find tumors and ovarian cancer cells by turning them into color. fluorescent green. On Target Laboratories, which has licensed the imaging agent through the OTC, markets the drug under the brand name Cytalux.

Low also co-directed the international study of the Phase 2 clinical trial showing a repurposed cancer drug to be 100% effective in defeating malaria within three days.

About Purdue Research Fund Office of Technology Trade

The Purdue Research Foundation Office of Technology Commercialization operates one of the most comprehensive technology transfer programs among leading research universities in the United States. The office is located at the Center for Innovation and Collaboration in Discovery Park in Purdue, adjacent to the Purdue campus. In fiscal year 2020, the office reported 148 agreements were completed with 225 technologies signed, 408 disclosures received, and 180 US patents granted. The office is managed by the Purdue Research Foundation, which received the 2019 Economic and Innovation Prosperity Colleges Award from the Association of Public and Land-grant Universities. In 2020, the IPWatchdog Institute ranked Purdue third nationally for start-ups and in the top 20 for patents. The Purdue Research Foundation is a private, nonprofit foundation established to advance the mission of Purdue University. Contact for more information.

Writer: Steve Martin,

Source: Brooke Beier,

Philip Low,

Timothy L. Ratliff,

Zhong-Yin Zhang,

Source by [author_name]


News7h: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, the World everyday world. Hot news, images, video clips that are updated quickly and reliably

Related Articles

Back to top button
Immediate Peak